Breast Cancer Subtypes and Mortality of Breast Cancer Patients With Brain Metastasis at Diagnosis: A Population-Based Study

Dong-Jie He, MM1,* De-Quan Yu, MM1,* Qi-Ming Wang, MM1, Zong-Yan Yu, MM1, Yu-Hong Qi, MD1, Qiu-Ju Shao, MM1*, and Hao Chang, MM1

Abstract

Background: Brain metastasis is an important cause of breast cancer-related death.

Aim: We evaluated the relationships between breast cancer subtype and prognosis among patients with brain metastasis at the initial diagnosis.

Methods: The Surveillance, Epidemiology, and End Results database was searched to identify patients with brain metastasis from breast cancer between 2010 and 2015. Multivariable Cox proportional hazard models were used to identify factors that were associated with survival among patients with initial brain metastases. The Kaplan–Meier method was used to compare survival outcomes according to breast cancer subtype.

Results: Among 752 breast cancer patients with brain metastasis at diagnosis, 140 patients (18.6%) underwent primary surgery and 612 patients (81.4%) did not undergo surgery, while 460 patients (61.2%) received chemotherapy and 292 patients (38.8%) did not receive chemotherapy. Multivariable analysis revealed that, relative to HR+/HER2– breast cancer, HR–/HER2– breast cancer was associated with significantly poorer overall survival (hazard ratio: 2.52, 95% confidence interval: 1.99–3.21), independent of age, sex, race, marital status, insurance status, grade, liver involvement, lung involvement, primary surgery, radiotherapy, and chemotherapy. The median overall survival intervals were 12 months for HR+/HER2–, 19 months for HR+/HER2+, 11 months for HR–/HER2+, and 6 months for HR–/HER2– (P < .0001). Relative to HR+/HER2– breast cancer, HR–/HER2– breast cancer was associated with a significantly higher risk of mortality among patients, and the association was stronger among patients who received chemotherapy (p for interaction = .005).

Conclusions: Breast cancer subtype significantly predicted overall survival among patients with brain metastasis at diagnosis.

Keywords
breast cancer, brain metastases, survival, tumor subtype, chemotherapy

What do we already know about this topic? Breast cancer patients with brain metastasis at diagnosis are rare, and further research on the subtypes of breast cancer and the prognosis of this population is warranted.

*These authors contributed equally to this work.

Corresponding Author:
Qiu-Ju Shao, Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, People’s Republic of China.
E-mail: shaoqfmmu@163.com

1Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, People’s Republic of China

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
How does your research contribute to the field? The current study showed that breast cancer subtype significantly predicted overall survival among patients with brain metastasis at diagnosis, and that chemotherapy played an interactive role in the association between breast cancer subtype and mortality. What are your research’s implications towards theory, practice, or policy? This study can provide a basis for future research and help develop care protocols for breast cancer patients with brain metastasis at diagnosis.

Introduction

Among solid tumors, breast cancer (BC) is the second most common cause of brain metastasis (BM), with a proportion of 4.4%–4.3% at first diagnosis. Metastatic breast cancer has a poor prognosis (median overall survival [OS]: 2–25.3 months), although the development of new and more effective treatment options has improved patient survival and increased the likelihood of patients developing BM. Previous studies have shown that HER2-negative and triple-negative breast cancer (TNBC) breast cancer subtypes have a higher incidence of brain metastasis (BM) at initial BC diagnosis; however, there are also studies that show that HER2-positive and TNBC subtypes have a higher incidence of BM at initial BC diagnosis. Thus, additional studies are needed to affirm the characteristics of breast cancer subtypes for BC patients with BM.

Data from a single institution have indicated that surgical resection and systemic therapy are effective treatments for BM in BC patients. Although the blood-brain barrier limits delivery of systemic treatments, the combination of chemotherapy and anti-angiogenic drugs can produce a high objective response rate to metastatic brain tumors in BC patients. Furthermore, retrospective cohort studies have demonstrated the survival benefit in metastatic breast cancer patients via the surgical removal of primary tumors and systemic treatments. Although previous studies have analyzed the relationship between newly diagnosed BM patients and subtypes, no further analysis of prognostic factors of breast cancer has been performed. Therefore, the present study conducted an analysis based on the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the association between the mortality of BC patients with BM and the molecular phenotypes of breast cancer.

Methods

Study Design and Data Source

The SEER database was searched to identify patients with BM at the initial diagnosis of stage IV breast cancer between 2010 and 2015. The SEER database contains data regarding demographic characteristics, clinical characteristics, tumor morphology, breast cancer subtype, stage at diagnosis, marital status, insurance status, first treatment, and survival outcomes. We signed SEER data-use agreements to access the data retrieved from this data-set. The retrospective study protocol was approved by our institutional review board, which waived the requirement to obtain informed consent as the patient data were anonymized.

The exclusion criteria were (1) a post-mortem diagnosis (based on autopsy or the death certificate), (2) no brain involvement at diagnosis, and (3) missing data regarding radiotherapy and surgery. Based on the inclusion and exclusion criteria, 752 patients were included in the analysis (Supplemental Figure 1). The study variables included age at diagnosis (<60 years and ≥60 years), sex (female and male), race (white, black, other, and unknown), American Joint Committee on Cancer (AJCC) T classification (T1, T2, T3, and T4), AJCC N classification (N0, N1, N2, and N3), disease grade (I, II, III, IV, and unknown), subtype (HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2−), marital status at diagnosis (married, unmarried, and unknown), insurance status (insured, uninsured, and unknown), bone involvement at diagnosis, lung involvement at diagnosis, lung involvement at diagnosis, survival status, survival time, and type of treatment (radiotherapy, chemotherapy, and surgery) for the primary site.

Statistical Analysis

Demographic and biological characteristics were compared using the chi-squared test. Univariate Cox proportional hazard models were used to identify factors that were associated with mortality. Multivariable analyses were performed to identify breast subtypes associated with mortality. We also adjusted for factors that, when added to the model, changed and matched hazard ratios by at least 10% and were clinically significant variables. Both non-adjusted and multivariate-adjusted models were used. The results were reported as hazard ratio (HR) and 95% confidence interval (CI). Subgroup analyses were performed according to age, liver involvement, lung involvement, surgery, radiotherapy, and chemotherapy. The Kaplan–Meier method and log-rank test were used to compare survival estimates. Landmark survival percentages at 12, 24, 36, and 60 months and median OS (95% CI) were reported by subtype. We constructed nomograms incorporating factors that may influence the prognosis of BC patients with BM. All statistical analyses were performed using R software (version 3.3.2; http://www.R-project.org) and Free Statistics software.
Results

Baseline Characteristics According to Breast Cancer Subtype

The SEER database included 752 American patients who were initially diagnosed with breast cancer and BM between 2010 and 2015. The patients included 10 men (1.3%) and 742 women (98.7%) (Table 1). Follow-up time was recorded up to November 2017, at which time 81.1% (N = 610) of patients had died. The breast cancer subtypes were HR+/HER2− for 338 patients (44.9%), HR+/HER2+ for 139 patients (18.5%), HR−/HER2+ for 102 patients (13.6%), and HR−/HER2− for 173 patients (23.0%). Patients were less likely to receive surgery as the primary treatment and more likely to receive chemotherapy. Studies have shown that brain metastases seem to be more likely to develop in patients with tumor grades II and III. Patients with HR−/HER2− tumors had decreased likelihoods of having bone involvement (HR−/HER2−: 43.4% vs HR+/HER2−: 74.3%), increased likelihoods of having lung involvement (HR−/HER2−: 52.0% vs HR+/HER2−: 41.7%), and increased multiple site metastasis.

Univariable and Multivariable Analyses

The univariable analyses revealed that mortality was associated with older age, male sex, black race, grade III disease, unmarried status, uninsured status, unknown insurance status, liver and lung involvement, no primary surgery, and no chemotherapy (Supplemental Table 1). These variables were entered into the multivariable model (Table 2). In the unadjusted model, patients with the HR+/HER2+ subtype had lower mortality than patients with the HR+/HER2− subtype (HR: .78, 95% CI: .62-.98), while higher mortality was observed for patients with the HR-/HER2+ subtype (HR: 1.04, 95% CI: .81-1.33) and the HR-/HER2− subtype (HR: 1.85, 95% CI: 1.51-2.25; p for trend < .0001). After adjusting for age, sex, race, marital status, insurance status, disease grade, liver involvement, lung involvement, primary surgery, radiotherapy, and chemotherapy, similar results were observed for patients with the HR+/HER2+ subtype (HR: .93, 95% CI: .73-1.19), the HR-/HER2+ subtype (HR: 1.33, 95% CI: 1.01-1.77), and the HR-/HER2− subtype (HR: 2.52, 95% CI: 1.99-3.21; p for trend < .001).

Subgroup Analyses

We performed stratified and interactive analyses to evaluate whether the relationships between breast cancer subtype and mortality were stable in the different subgroups (Table 3). Chemotherapy played an interactive role in the association between breast cancer subtype and mortality (p for interaction = .005). The trend was significant among patients who did not receive chemotherapy (HR+/HER2+, HR: .98 [95% CI: .66-1.48]; HR−/HER2+, HR: 2.45 [95% CI: 1.47-4.09]; and HR−/HER2−, HR: 2.14 [95% CI: 1.39-3.30]; p for trend < .001), although it was even stronger among patients who received chemotherapy (HR+/HER2+, HR: .78 [95% CI: .56-1.06]; HR−/HER2+, HR: 1.01 [95% CI: .72-1.42]; HR−/HER2−, HR: 2.57 [95% CI: 1.89-3.48]; p for trend < .001). Similar albeit non-significant results were observed according to age (p for interaction = .32), primary surgery (p for interaction = .31), and radiotherapy (p for interaction = .57) (Table 3).

Survival Curve Analysis and Prognostic Score

The median OS intervals were 12 months for HR+/HER2−, 19 months for HR+/HER2+, 11 months for HR−/HER2+, and 6 months for HR−/HER2− (P < .0001, Supplemental Figure 2A, Supplemental Table 2). The median OS intervals were 6 months for patients who did not receive chemotherapy and 15 months for patients who did receive chemotherapy (P < .0001, Supplemental Figure 2B). Furthermore, the score of each variable was determined according to the regression coefficient of each variable in the multivariate Cox model, so as to construct the overall prognosis score integrating these 6 parameters (Supplemental Figure 3). The nomogram showed medium accuracy in predicting the OS, with a C-index of .63 (95% CI = .60-.66) (Supplemental Figure 4).

Discussion

In breast cancer cases, BM is a type of distant metastasis that is associated with a poor prognosis.5 In the US, 12% of women will be diagnosed with breast cancer during their lifetime.18 In addition, the mortality outcomes vary according to breast cancer subtype in patients with BM, despite the use of various active treatments.19 Therefore, the present study aimed to evaluate whether mortality varied according to subtype in patients from the SEER database who were diagnosed with stage IV breast cancer and BM, as well as the potential effects of different treatment strategies.

The HR+ and TNBC subtypes reportedly have the highest rates of BM,20 and the subtype distributions in our study were similar to previously reported results.21 The present study revealed that patients with the HR+/HER2− subtype had the highest incidences of bone metastasis, liver metastasis, and lung metastasis. Furthermore, bone metastasis was the most common location among all patients, which suggests that this group of patients may have special molecular/biological characteristics and require careful screening and follow-up. Further studies are needed to determine whether the T classification, N classification, and pathological grade are related to the incidence of BM.
Table 1. Demographic and clinical characteristics de novo IV patients with brain metastasis grouped by subtypes.

| Variables            | All Participants n (%) | HR+/HER2- n (%) | HR+/HER2+ n (%) | HR-/HER2+ n (%) | HR-/HER2- n (%) | P   |
|----------------------|------------------------|-----------------|-----------------|-----------------|-----------------|-----|
|                      | n = 752(100)           | n = 338(44.9)   | n = 139(18.5)   | n = 102(13.6)   | n = 173(23.0)   |     |
|                      |                        |                 |                 |                 |                 | .151|
| Age (years)          |                        |                 |                 |                 |                 | .358|
| <60                  | 396 (52.7)             | 163 (48.2)      | 80 (57.6)       | 59 (57.8)       | 94 (54.3)       |     |
| ≥60                  | 356 (47.3)             | 175 (51.8)      | 59 (42.4)       | 43 (42.2)       | 79 (45.7)       | .377|
| Sex                  |                        |                 |                 |                 |                 |     |
| Female               | 742 (98.7)             | 334 (98.8)      | 135 (97.1)      | 101 (99)        | 172 (99.4)      |     |
| Male                 | 10 (1.3)               | 4 (1.2)         | 4 (2.9)         | 1 (1.0)         | 1 (.6)          |     |
| Race                 |                        |                 |                 |                 |                 |     |
| White                | 541 (71.9)             | 251 (74.3)      | 95 (68.3)       | 72 (70.6)       | 123 (71.1)      |     |
| Black                | 149 (19.8)             | 62 (18.3)       | 27 (19.4)       | 20 (19.6)       | 40 (23.1)       |     |
| Other\(^1\)          | 62 (8.2)               | 25 (7.4)        | 17 (12.2)       | 10 (9.8)        | 10 (5.8)        |     |
| AJCC T stage         |                        |                 |                 |                 |                 | .706|
| I                    | 95 (12.6)              | 40 (11.8)       | 22 (15.8)       | 8 (7.8)         | 25 (14.5)       |     |
| 2                    | 204 (27.1)             | 98 (29.0)       | 33 (23.7)       | 27 (26.5)       | 46 (26.6)       |     |
| 3                    | 127 (16.9)             | 59 (17.5)       | 22 (15.8)       | 16 (15.7)       | 30 (17.3)       |     |
| 4                    | 326 (43.4)             | 141 (41.7)      | 62 (44.6)       | 51 (50.0)       | 72 (41.6)       |     |
| AJCC N stage         |                        |                 |                 |                 |                 | .022*|
| 0                    | 179 (23.8)             | 97 (28.7)       | 28 (20.1)       | 22 (21.6)       | 32 (18.5)       |     |
| 1                    | 350 (46.5)             | 153 (45.3)      | 68 (48.9)       | 43 (42.2)       | 86 (49.7)       |     |
| 2                    | 97 (12.9)              | 45 (13.3)       | 22 (15.8)       | 14 (13.7)       | 16 (9.2)        |     |
| 3                    | 126 (16.8)             | 43 (12.7)       | 21 (15.1)       | 23 (22.5)       | 39 (22.5)       |     |
| Grade                |                        |                 |                 |                 |                 | <.001****|
| I                    | 29 (3.9)               | 25 (7.4)        | 3 (2.2)         | 0 (0)           | 1 (.6)          |     |
| II                   | 224 (29.8)             | 134 (39.6)      | 42 (30.2)       | 24 (23.5)       | 24 (13.9)       |     |
| III                  | 355 (47.2)             | 113 (33.4)      | 66 (47.5)       | 56 (54.9)       | 120 (69.4)      |     |
| IV                   | 8 (1.1)                | 1 (.3)          | 1 (.7)          | 2 (2.0)         | 4 (2.3)         |     |
| Unknown              | 136 (18.1)             | 65 (19.2)       | 27 (19.4)       | 20 (19.6)       | 24 (13.9)       |     |
| Marital status       |                        |                 |                 |                 |                 | .213|
| Married              | 408 (54.3)             | 180 (53.3)      | 74 (53.2)       | 52 (51.0)       | 102 (59)        |     |
| Unmarried\(^2\)      | 300 (39.9)             | 131 (38.8)      | 60 (43.2)       | 43 (42.2)       | 66 (38.2)       |     |
| Unknown              | 44 (5.9)               | 27 (8.0)        | 5 (3.6)         | 7 (6.9)         | 5 (2.9)         |     |
| Insurance status     |                        |                 |                 |                 |                 | .883|
| Insured\(^3\)        | 51 (6.8)               | 22 (6.5)        | 10 (7.2)        | 8 (7.8)         | 11 (6.4)        |     |
| Uninsured            | 691 (91.9)             | 313 (92.6)      | 126 (90.6)      | 92 (90.2)       | 160 (92.5)      |     |
| Unknown              | 10 (1.3)               | 3 (9)           | 3 (2.2)         | 2 (2.0)         | 2 (1.2)         |     |
| Bone involvement     |                        |                 |                 |                 |                 | <.001****|
| No                   | 261 (34.7)             | 87 (25.7)       | 35 (25.2)       | 41 (40.2)       | 98 (56.6)       |     |
| Yes                  | 491 (65.3)             | 251 (74.3)      | 104 (74.8)      | 61 (59.8)       | 75 (43.4)       |     |
| Liver involvement    |                        |                 |                 |                 |                 | <.001****|
| No                   | 508 (67.6)             | 245 (72.5)      | 87 (62.6)       | 49 (48.0)       | 127 (73.4)      |     |
| Yes                  | 244 (32.4)             | 93 (27.5)       | 52 (37.4)       | 53 (52.0)       | 46 (26.6)       |     |
| Lung involvement     |                        |                 |                 |                 |                 | .049*|
| No                   | 405 (53.9)             | 197 (58.3)      | 78 (56.1)       | 47 (46.1)       | 83 (48.0)       |     |
| Yes                  | 347 (46.1)             | 141 (41.7)      | 61 (43.9)       | 55 (53.9)       | 90 (52.0)       |     |
| Primary surgery      |                        |                 |                 |                 |                 | .12 |
| No                   | 612 (81.4)             | 276 (81.7)      | 118 (84.9)      | 87 (85.3)       | 131 (75.7)      |     |
| Yes                  | 140 (18.6)             | 62 (18.3)       | 21 (15.1)       | 15 (14.7)       | 42 (24.3)       | .196|

(continued)
Table 1. (continued)

| Variables | All Participants n (%) | HR+/HER2- n (%) | HR+/HER2+ n (%) | HR-/HER2+ n (%) | HR-/HER2- n (%) |
|-----------|------------------------|-----------------|----------------|----------------|----------------|
| n = 752(100) | | | | | | |
| No        | 218 (29.0)            | 98 (29.0)       | 45 (32.4)      | 21 (20.6)      | 54 (31.2)      |
| Yes       | 534 (71.0)            | 240 (71)        | 94 (67.6)      | 81 (79.4)      | 119 (68.8)     |
| Chemotherapy | <.001***            | | | | | |
| No        | 292 (38.8)            | 185 (54.7)      | 39 (28.1)      | 22 (21.6)      | 46 (26.6)      |
| Yes       | 460 (61.2)            | 153 (45.3)      | 100 (71.9)     | 80 (78.4)      | 127 (73.4)     |

Abbreviations: AJCC, American Joint Committee on Cancer; HR, hormone receptor; HER2, human epidermal growth factor 2
*P < .05; **P < .01; ***P < .001.
Notes: data presented are N (%). HR+/HER2-,(Luminal A); HR+/HER2+, (Luminal B); HR-/HER2+,(HER2 enriched); HR-/HER2-,(Triple Negative). (1) including American Indian/AK Native, Asian/Pacific Islander; (2) including Divorced/Separated/Single (never married)/Unmarried or Domestic Partner/Widowed; (3) including Any Medicaid/Insured (No specifics).

Table 2. Association between breast subtypes and mortality.

| Breast Subtypes | Non-adjusted | Adjust I | Adjust II | Adjust III |
|-----------------|--------------|----------|-----------|------------|
|                 | P            | P        | P         | P          |
| HR+/HER2-       | .78 (.62–.98) | .030*    | .81 (.64–1.02) | .069       |
| HR+/HER2+       | 1.04 (.81–1.33)| .782     | 1.05 (.81–1.35) | .722       |
| HR-/HER2+       | 1.85 (1.51–2.25) | <.001*** | 1.96 (1.60–2.40) | <.001***   |
| HR-/HER2-       | 1.85 (1.51–2.25) | <.001*** | 1.88 (1.52–2.33) | <.001***   |
| Abbreviations: CI, confidence interval; ORs, Hazard ratios, Ref.: reference.
*P < .05; **P < .01; ***P < .001.
Notes: data presented are HRs and 95% CIs. Adjust I model adjusts for Age, Sex and Insurance status; adjust II model adjusts for adjust I+ Grade, Marital status; adjust III model adjusts for adjust II+ Liver involvement, Lung involvement, Surgery, Radiation, and Chemotherapy.

Table 3. Subgroup analyses of the association breast subtypes and mortality.

| Confounding factor category | Breast Subtypes | P for Trend | P for Interaction |
|-----------------------------|-----------------|-------------|-------------------|
| Age (years)                 | HR+/HER2-       | HR+/HER2+   | HR-/HER2+         | HR-/HER2-     |
| <60                         | 1 (Ref)         | .93 (.65,1.31) | 1.25 (.84,1.85) | 2.68 (1.88,3.81) | <.001*** |
| ≥60                         | 1 (Ref)         | .99 (.68,1.43) | 1.50 (.97,2.31) | 2.42 (1.70,3.44) | <.001*** |
| Liver involvement           | No              | 1 (Ref)     | 1.04 (.76,1.41) | 1.04 (.70,1.54) | 2.32 (1.72,3.12) | <.001*** |
|                             | Yes             | 1 (Ref)     | .78 (.51,1.21)  | 1.51 (.97,2.34) | 2.86 (1.81,4.52) | <.001*** |
| Lung involvement            | No              | 1 (Ref)     | .76 (.54,1.06)  | .82 (.54,1.24)  | 2.27 (1.59,3.23) | <.001*** |
|                             | Yes             | 1 (Ref)     | 1.15 (.79,1.67) | 2.04 (1.36,3.05) | 2.91 (2.06,4.12) | <.001*** |
| Primary surgery             | No              | 1 (Ref)     | 1.03 (.79,1.35) | 1.48 (1.08,2.02) | 2.82 (2.14,3.72) | <.001*** |
|                             | Yes             | 1 (Ref)     | .42 (.20,0.87)  | .60 (27,131)    | 1.36 (80,231)   | .278 |
| Radiation                   | No              | 1 (Ref)     | .97 (.60,1.55)  | 1.75 (.96,3.18) | 2.53 (1.59,4.03) | <.001*** |
|                             | Yes             | 1 (Ref)     | .89 (.66,1.20)  | 1.27 (.92,1.77) | 2.73 (2.04,3.66) | <.001*** |
| Chemotherapy                | No              | 1 (Ref)     | .98 (.66,1.48)  | 2.45 (1.47,4.09) | 2.14 (1.39,3.30) | <.001*** |
|                             | Yes             | 1 (Ref)     | .78 (.56,1.06)  | 1.01 (.72,1.42) | 2.57 (1.89,3.48) | <.001*** |

Abbreviations: CI, confidence interval; ORs, Hazard ratios, Ref.: reference.
*P < .05; **P < .01; ***P < .001.
Notes: data presented are HRs and 95% CIs. Adjusted for Age, Sex, Race, AJCC T stage, AJCC N stage, Grade, Marital status, Insurance status, Bone involvement, Liver involvement, Lung involvement, Surgery, Radiation, and Chemotherapy.
We found that, among patients who were diagnosed with BM and breast cancer, poor OS was significantly associated with older age, black race, grade III disease, unmarried status, uninsured and unknown insurance status, liver and lung involvement, no primary surgery, no radiotherapy, and no chemotherapy. Similarly, a previous study of US patients with stage IV breast cancer revealed that OS was significantly associated with age, hormone receptor status, insured status, breast subtype, and stage at diagnosis.\textsuperscript{10,22} Our multivariable model also revealed that, relative to patients with the HR+/HER2– subtype, higher mortality was observed for patients with the HR–/HER2+ subtype (HR: 1.33) and the HR–/HER2– subtype (HR: 2.52, p for trend < .0001). Another previous study has indicated that the breast cancer subtype influenced survival after the development of distant metastasis.\textsuperscript{23,24}

Among patients in the US, the median OS values for the 4 breast cancer subtypes ranged from 6 months to 19 months, which is shorter than in the Chinese population, based on a review of 2087 patients with metastatic breast cancer who had a median OS of 23.7 months after the diagnosis of BM.\textsuperscript{2} Breast cancer-specific outcomes reflect the disease-free interval and OS interval.\textsuperscript{25} Therefore, we analyzed OS according to breast cancer subtype among patients with BM, which revealed that the HR+/HER2+ subtype was associated with the longest median OS (19 months), while the HR–/HER2– subtype was associated with the shortest median OS (6 months). Patients with BM might benefit from increased surveillance and radiotherapy.\textsuperscript{26,27} That population-based cohort study detected a significant difference in mortality among patients with BM, although it lacked data regarding number of BMs, site, and radiotherapy.\textsuperscript{14} We also built a prediction model in the collection of newly diagnosed patients with BMs to better predict the relationship between subtypes and mortality, and the accuracy and specificity of prediction needs to be further verified.

Surgery for the primary tumor was associated with significantly improved survival in patients with a single distant metastasis from metastatic TNBC.\textsuperscript{28} Real-world data also indicate that neoadjuvant systemic therapy and surgery provide better survival than surgery alone.\textsuperscript{29} The present study provides population-based estimates of the proportion of patients who underwent surgery as primary treatment, which may be beneficial for improving their OS outcomes. There is a lack of consensus regarding the efficacy of chemoradiotherapy for BM from breast cancer, although the combined treatment appears to be safe.\textsuperscript{30-32} A single-arm phase IIIb clinical trial also indicated that HER2-targeted therapy and chemotherapy were well tolerated.\textsuperscript{33} The blood-brain barrier can make brain tumors difficult to treat using pharmacological agents, although some monoclonal antibodies and chemotherapy drugs are reasonable options for patients with BM.\textsuperscript{34-36} Subgroup analysis in the present study revealed that the association between breast subtypes and mortality stably existed except in the case of primary surgery. Besides, the association was more significant in the chemotherapy group than non-chemotherapy participants (p for trend = .005). We hypothesized that a higher number of patients with multiple site metastases were included for HR–/HER2– subtype, and the risk of death due to side effects after chemotherapy was increased.

The present study has several strengths, including the relatively large population-based cohort, adjustment of the analyses for potential confounding factors, the subtype-specific analyses, and the finding that chemotherapy provided an OS benefit for patients with initial BM. However, the present study also has several limitations that must be considered when interpreting the results. First, the chemotherapy data were retrieved from the SEER database, which provides limited information regarding the specific chemotherapy regimen and its ability to cross the blood-brain barrier. Second, detailed information regarding radiotherapy could not be retrieved from the SEER database. Third, data regarding endocrine therapy could not be retrieved from the SEER database, and this treatment might attenuate the HR values for OS because it is positively correlated with OS.\textsuperscript{37} Fourth, it is not possible to obtain information regarding the treatment of patients with BM, and the SEER database also has various other potential limitations that should be considered.

**Conclusion**

The present study evaluated SEER data regarding patients with BM at the initial diagnosis of breast cancer and indicates that the breast cancer subtype independently predicted the mortality of patients with brain metastasis at the initial diagnosis.

**Acknowledgments**

We thank the SEER database for providing valuable data-set and our colleagues from the department for their support of this study. We would like to thank Editage (www.editage.cn) for English language editing.

**Author Contributions**

DJH and DQY analyzed the data and drafted the paper. QMW and YHQ collected the data, QMW and YHQ analyzed the data. QJS conceived and designed the idea to this paper. All authors approved the final version for submission.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.
Ethical Approval
We signed SEER data-use agreements to access the data retrieved from this data-set. The retrospective study protocol was approved by the institutional review board at the Second Affiliated Hospital of Air Force Medical University (TDLL-KY-202103-02), which waived the requirement for informed consent based on the analysis of de-identified patient data.

ORCID iDs
Dongjie He https://orcid.org/0000-0002-4494-9950
Qiu-Ju Shao https://orcid.org/0000-0003-4084-4374

Supplemental Material
Supplemental material for this article is available online.

References
1. Bailleux C, Eberst L, Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer. 2021;124(1):142-155.
2. Li Y, Li Q, Mo H, Guan X, Lin S, Wang Z, et al. Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China. Breast. 2021;55:30-36.
3. Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017;3(8):1069-1077.
4. Leone JP, Leone J, Zwenger AO, Iturbe J, Leone BA, Vallejo CT. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis. Eur J Cancer. 2017;74:17-25.
5. Kim JS, Kim IA. Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Ther Adv Med Oncol. 2020;12:175883592096117.
6. Meattini I, Andratschke N, Kirby AM, Sviri G, Offerens BV, Poortmans P, et al. Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. Clin Transl Oncol. 2020;22(10):1698-1709.
7. Tian J, Luo Y, Xiang J, Tang J. Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. J Neuro Oncol. 2017;135(2):217-227.
8. Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2020.
9. Wang Y, Ji Z, Lin FH, Wang XH, Wan-Ming H, He ZQ, et al. Outcome and prognostic value of treatment for brain metastases and the primary tumor in patients with breast cancer brain metastases. Clin Neurol Neurosurg. 2018;170:43-46.
10. Gori S, Puglisi F, Moroso S, Fabi A, La Verde N, Frassoldati A, et al. The HERBA Study: a retrospective multi-institutional Italian Study on patients with brain metastases from HER2-positive breast cancer. Clin Breast Cancer. 2019;19(4):e501-e510.
11. Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, et al. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020;22(1):131.
12. Wang K, Shi Y, Li ZY, Xiao YL, Li J, Zhang X, et al. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study. Eur J Surg Oncol. 2019;45(8):1364-1372.
13. Kotecki N, Lefranc F, Devriendt D, Awada A. Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives. Ther Adv Med Oncol. 2018;10:175.
14. Xiong Y, Cao H, Zhang Y, Pan Z, Dong S, Wang G, et al. Nomogram-predicted survival of breast cancer brain metastasis: a SEER-based population study. World Neurosurg. 2019;128:e823-e834.
15. Zimmerman BS, Seidman D, Cascetta KP, Ru M, Mosherie E, Tiersten A. Prognostic factors and survival outcomes among patients with breast cancer and brain metastases at diagnosis: a national cancer database analysis. Oncology. 2021;99(5):280-291.
16. Liu D, Wu J, Lin C, Andriansi L, Ding S, Shen K, et al. Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study. Front Oncol. 2020;10:580112.
17. Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat. 2020;184(2):559-565.
18. Bao Y, Zhang S, Chen Z, Chen AT, Ma J, Deng G, et al. Synergistic chemotherapy for breast cancer and breast cancer brain metastases via paclitaxel-loaded oleic acid nanoparticles. Mol Pharm. 2020;17(4):1343-1351.
19. Jeon W, Jang BS, Jeon SH, Kim JH, Kim YJ, Kim SH, et al. Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort. Breast J. 2018;24(6):920-926.
20. Kim JS, Kim K, Jung W, Shin KH, Im SA, Kim HJ, et al. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12). Breast Cancer Res Treat. 2021.
21. Jang G, Lee SS, Ahn JH, Jung KH, Lee H, Gong G, et al. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Res Treat. 2011;128(1):171-177.
22. Li X, Zhang X, Liu J, Shen Y. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. BMC Cancer. 2020;20(1):1102.
23. Van Mechelen M, Van Herck A, Punie K, Nevelsteen I, Smeets A, Neven P, et al. Behavior of metastatic breast cancer according to subtype. Breast Cancer Res Treat. 2020;181(1):115-125.
24. Arciero CA, Guo Y, Jiang R, Behera M, O'Regan R, Peng L, et al. ER(+)HER2(+) Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER(-)/HER2(+) Breast Cancer. *Clin Breast Cancer*. 2019;19(4):236-245.

25. Honda Y, Aruga T, Yamashita T, Miyamoto H, Horiguchi K, Kitagawa D, et al. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications. *Jpn J Clin Oncol*. 2015;45(8):713-718.

26. Kim JS, Kim K, Jung W, Shin KH, Im SA, Kim HJ, et al. Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12). *Breast*. 2020;49:41-47.

27. Mainwaring W, Bowers J, Pham N, Pezzi T, Shukla M, Bonnen M, et al. Stereotactic radiosurgery versus whole brain radiation therapy: a propensity score analysis and predictors of care for patients with brain metastases from breast cancer. *Clin Breast Cancer*. 2019;19(2):e343-e351.

28. Gu Y, Wu G, Zou X, Huang P, Yi L. Prognostic value of site-specific metastases and surgery in de novo stage iv triple-negative breast cancer: a population-based analysis. *Med Sci Mon Int Med J Exp Clin Res*. 2020;26:e920432.

29. Ma L, Mi Y, Cui S, Wang H, Fu P, Yin Y, et al. Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China. *Sci Rep*. 2020;10(1):18132.

30. Borius PY, Regis J, Carpentier A, Kalamarides M, Valery CA, Latorzeff I. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review. *Cancer Metastasis Rev*. 2021.

31. Liu L, Chen W, Zhang R, Wang Y, Liu P, Lian X, et al. Radiotherapy in combination with systemic therapies for brain metastases: current status and progress. *Cancer Biol Med*. 2020;17(4):910-922.

32. Steindl A, Berghoff AS. Brain metastases in metastatic cancer: a review of recent advances in systemic therapies. *Expert Rev Anticancer Ther*. 2020;1:1-15.

33. Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(). *Ann Oncol*. 2020;31(10):1350-1358.

34. Ren D, Cheng H, Wang X, Vishnoi M, Teh BS, Rostomily R, et al. Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience. *Ther Adv Med Oncol*. 2020;12:1758.

35. Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, et al. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. *Breast Cancer Res Treat*. 2018;171(3):637-648.

36. Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. *Breast Cancer Res Treat*. 2019;177(2):401-408.

37. Bergen ES, Berghoff AS, Medjedovic M, Radas M, Fitzal F, Bago-Horvath Z, et al. Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases. *Clin Cancer Res*. 2019;25(9):2737-2744.